AbbVie: Q4 EPS down 22%

(CercleFinance.com) - AbbVie reports adjusted EPS of $2.
79 for Q4 2023, down 22.5%, with an adjusted operating margin of 43.8% on sales of $14.3bn, down 5.4%. NB: pmt +1%.

The healthcare group points out that revenue growth in neuroscience (+22.6%) and aesthetics (+6.4%) was more than offset by declines in immunology (-12.3%) and oncology (-7.4%).

With adjusted EPS down 19.3% to $11.11 for FY 2023, AbbVie is targeting $11.05 to $11.25 for 2024, and reinstates its forecast of high single-digit in annual revenue growth through 2029.


Copyright (c) 2024 CercleFinance.com. All rights reserved.